Randy Baron from Pinnacle Associates discusses Amyris's lead in synthetic biology

Randy Baron, Portfolio Manager at Pinnacle Associates, gives an overview of the Synthetic Biology space. Randy thinks "the 21st century is going to be a century of biology," and he discusses all the ways synthetic biology can change the world and why he thinks Amyris (AMRS) could be the biggest winner given their head start in the space.Randy's Barron's write up on Synthetic Biology: https://www.barrons.com/articles/an-investors-guide-to-the-promise-of-synthetic-biology-51623275429My thread with AMRS management quotes: https://twitter.com/AndrewRangeley/status/1407372814466826240 Chapters0:00 Intro1:00 Synthetic Biology Overview9:00 Amyris's founding treating malaria12:30 Squalene oil overview19:00 What's the barrier to entry for synthetic biology?23:45 Why is scaling so hard in synthetic biology?25:05 Comping AMRS to ZY (Zymergen)31:45 Discussing the value of AMRS's scaled molecules and pipeline35:00 AMRS's consumer brands37:20 Is having consumer brands and a research arm too good to be true?39:20 How AMRS could improve vaccines44:55 AMRS's zero calorie product, Purecane49:50 Quantifying the value of AMRS's different parts (SOTP)1:01:00 Discussing management and John Doerr's involvement1:06:00 How do you evaluate AMRS's CEO?1:11:45 Final thoughts